SAN
DIEGO, March 15, 2022 /PRNewswire/
-- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the
"Company"), a biopharmaceutical company focused on the development
of new solid tumor cancer therapies, today announces that it will
be presenting data at the 2022 American Association for Cancer
Research (AACR) Annual Meeting. The AACR 2022 Annual Meeting
will be held from April 8 through April 13,
2022 in New Orleans.
Data Presentation:
Track 24: Experimental and Molecular
Therapeutics
Session PO.ET02.01 - Mechanisms of Drug Action 1
1843 / 15 - Dianhydrogalactitol (VAL-083) for the Treatment
of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters
for Crossing the Blood Brain Barrier (BBB)
(Presentation Time: Monday, April
11, 2022 - 1:30 to 5:00 pm
CT)
About Kintara
Located in San
Diego, California, Kintara is dedicated to the development
of novel cancer therapies for patients with unmet medical needs.
Kintara is developing two late-stage, Phase 3-ready therapeutics
for clear unmet medical needs with reduced risk development
programs. The two programs are VAL-083 for Glioblastoma
Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer
(CMBC).
VAL-083 is a "first-in-class," small-molecule
chemotherapeutic with a novel mechanism of action that has
demonstrated clinical activity against a range of cancers,
including central nervous system, ovarian and other solid tumors
(e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical
trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these
prior NCI-sponsored clinical studies, Kintara is
currently advancing VAL-083 in the GBM AGILE study to support the
development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage
photodynamic therapy platform that holds promise as a localized
cutaneous, or visceral, tumor treatment as well as in other
potential indications. REM-001 therapy has been previously
studied in four Phase 2/3 clinical trials in patients with CMBC who
had previously received chemotherapy and/or failed radiation
therapy. With clinical efficacy to date of 80% complete responses
of CMBC evaluable lesions, and with an existing robust safety
database of approximately 1,100 patients across multiple
indications, Kintara is advancing the REM-001 CMBC
program to late-stage pivotal testing.
For more information, please visit www.kintara.com or
follow us on Twitter
at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the GBM AGILE study. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the impact
of the COVID-19 pandemic on the Company's operations and clinical
trials; the Company's ability to develop, market and sell products
based on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's
filings with the SEC, including the Company's Annual Report on Form
10-K for the year ended June 30,
2021, the Company's Quarterly Reports on Form 10-Q, and the
Company's Current Reports on Form 8-K.
CONTACTS
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-data-presentation-at-the-2022-american-association-for-cancer-research-annual-meeting-301502520.html
SOURCE Kintara Therapeutics